Insmed Incorporated was removed from the NASDAQ-100 Index on 19 June 2026, a technical setback that does not alter the company's fundamental outlook. Investor attention remains fixed on upcoming clinical data for its experimental lung drug TPIP, which analysts view as a potential turning point for Insmed's rare respiratory disease portfolio. The March 2026 ENCORE Phase 3b readout for ARIKAYCE showed improved culture conversion and symptom scores, supporting plans to seek a broader MAC lung disease label in the second half of 2026. While some analysts project revenue reaching about $3.6 billion and earnings of roughly $160 million by 2029 under cautious assumptions, the index removal may prompt investors to reassess confidence in those more pessimistic scenarios.
Insmed IncUpcoming TPIP clinical data is a potential turning point, but outcome unknown; index removal is technical.